What is HRT, and why does the specific formulation matter?
Hormone replacement therapy (HRT) — increasingly called menopausal hormone therapy (MHT) in clinical guidelines — refers to clinician-prescribed estrogen, or a combination of estrogen and progestogen, used to address the hormonal changes of menopause. The formulation matters significantly: different routes (transdermal, oral, vaginal), different hormones (estradiol versus conjugated equine estrogen; progesterone versus synthetic progestogens), and different doses carry different evidence profiles.
Women who have not had a hysterectomy require progestogen alongside estrogen to protect the uterine lining (endometrium) from unopposed estrogen stimulation. Women who have had a hysterectomy can use estrogen alone. This distinction drives much of the risk differentiation in the literature.
What are the pros of HRT for women?
Vasomotor symptom relief
Hot flashes and night sweats — collectively called vasomotor symptoms — affect approximately 75% of women during the menopause transition. They can be severe enough to disrupt sleep, work performance, and quality of life. Systemic estrogen is the most effective treatment for vasomotor symptoms, with clinical trials consistently showing 70–90% reduction in hot flash frequency and severity. No non-hormonal therapy approaches this level of efficacy for moderate-to-severe symptoms.
Genitourinary health
Estrogen deficiency causes significant changes to vaginal tissue: thinning, reduced lubrication, elevated pH, and increased susceptibility to irritation and infection. Urinary urgency and frequency also increase with menopause-related estrogen decline. These genitourinary syndrome of menopause (GSM) symptoms respond well to both systemic and local (vaginal) estrogen therapy. Local low-dose vaginal estrogen carries minimal systemic absorption and is considered low-risk even for women who cannot use systemic HRT.
Bone density preservation
Estrogen is a primary regulator of bone remodeling. Menopause-related estrogen decline accelerates bone turnover, with the first 5–10 years post-menopause representing the period of most rapid bone density loss. HRT is one of the most effective interventions for preserving bone mineral density and reducing fracture risk in postmenopausal women. The North American Menopause Society recognizes bone health as an established non-symptomatic benefit of HRT.
Mood and sleep
Sleep disruption from night sweats and mood disturbances during perimenopause are frequently reported symptoms. HRT’s effects on sleep are partly secondary (reduced night sweats allow uninterrupted sleep) and partly direct — estrogen and progesterone both have neurological activity. For many women, HRT during the menopause transition produces meaningful improvements in sleep quality and mood stability.
Cardiovascular benefit in early menopause (timing hypothesis)
The timing hypothesis — now well-supported by observational and trial data — holds that estrogen initiated within 10 years of menopause onset, or before age 60, in healthy women may confer cardiovascular protection. This contrasts with the adverse cardiovascular signals seen in the WHI, where average participant age was 63 and many had pre-existing cardiovascular disease. The ELITE trial and Danish Osteoporosis Prevention Study support improved cardiovascular biomarkers and clinical outcomes in women who start HRT early in the menopause transition.
The real question is no longer “is HRT dangerous?” but “what does today’s evidence say for someone with my history, symptoms, and risk factors?”
What are the cons and risks of HRT?
Breast cancer risk
The breast cancer question is the most prominent concern about HRT. The evidence is nuanced:
- Estrogen alone (for women after hysterectomy) is not associated with increased breast cancer risk in most analyses, and some studies suggest a possible reduction in risk with conjugated estrogen alone in women who are obese.
- Combined estrogen-progestogen HRT is associated with a small increased breast cancer risk that becomes apparent after approximately 5 years of use. The absolute risk increase is modest — the 2022 Menopause Society statement estimates approximately 1 additional case per 1,000 women per year for combined therapy.
- Micronized progesterone (bioidentical, as opposed to synthetic progestins like medroxyprogesterone acetate) shows a more favorable breast cancer risk profile in observational studies. The WHI used medroxyprogesterone acetate; the risk difference between synthetic progestogens and micronized progesterone is clinically significant and guides modern prescribing.
Venous thromboembolism (VTE)
Oral estrogen increases VTE risk by approximately twofold compared to non-use, due to first-pass hepatic effects on clotting factors. Transdermal estradiol does not show a significant VTE signal in large observational studies — it bypasses first-pass liver metabolism. Current guidelines recommend transdermal delivery for women with elevated VTE risk factors.
Stroke risk
Oral estrogen is associated with a small increase in ischemic stroke risk. Transdermal estrogen does not show this association in current data. Stroke risk is also highly age-dependent; the absolute risk is much lower in women in their early fifties than in older women.
Women who should not use systemic HRT
Absolute contraindications to systemic estrogen-containing HRT include: history of estrogen receptor-positive breast cancer, unexplained vaginal bleeding, active liver disease, history of VTE (with some exceptions under specialist guidance), and history of stroke or transient ischemic attack. These are evaluated during clinical intake.
HRT pros and cons at a glance
| Category | Pro / benefit | Con / risk (and modifiers) |
|---|---|---|
| Vasomotor symptoms | 70–90% reduction in hot flashes and night sweats | Most effective option available; risk limited to individual HRT profile |
| Bone density | Preserves BMD; reduces fracture risk | Effect reverses after stopping HRT; duration question is individual |
| Breast cancer risk | Estrogen-only: neutral or reduced risk in some analyses | Combined E+P: ~1 extra case per 1,000 women/year after ~5 years; micronized progesterone preferred |
| VTE (blood clot) risk | Transdermal estrogen: no significant VTE signal | Oral estrogen: ~2x VTE risk vs. non-use; transdermal preferred for at-risk women |
| Cardiovascular health | Timing hypothesis: cardioprotective if started <10 years post-menopause | Started late (>10 years post-menopause): less favorable or neutral |
| Genitourinary / mood / sleep | Well-documented improvement in GSM, sleep quality, mood | Not uniformly applicable; individual response varies |
Why did the WHI paint such a negative picture, and how has that changed?
The 2002 Women’s Health Initiative results caused widespread discontinuation of HRT and shaped a generation of clinical practice. In retrospect, several aspects of the study population and design limit the generalizability of the findings to younger, recently menopausal women:
- The average participant age was 63 — approximately 12 years past the typical menopause onset — and a significant proportion had pre-existing cardiovascular disease or risk factors.
- The study used oral conjugated equine estrogen and medroxyprogesterone acetate, not the transdermal estradiol and micronized progesterone preferred in modern prescribing.
- The absolute risk increases, when communicated as relative risks, were widely misinterpreted. For a 50-year-old woman in good health, the absolute risk difference for most outcomes was small.
Re-analyses of the WHI by age subgroup, subsequent trials including the ELITE study, and the 2022 Menopause Society position statement have substantially rehabilitated HRT’s risk-benefit picture for appropriate candidates — women with significant menopausal symptoms, aged 50–59 or within 10 years of menopause, using transdermal estradiol and micronized progesterone.
Frequently asked questions
What are the main pros of HRT for women?
The most consistently documented benefits of HRT for women in menopause include relief of vasomotor symptoms (hot flashes, night sweats), reduced genitourinary symptoms (vaginal dryness, urinary urgency), improved sleep quality, preservation of bone density (reduced fracture risk), and for many women improvements in mood and cognitive clarity during the menopause transition. Symptom relief is often significant for women with moderate-to-severe vasomotor symptoms.
What are the main cons or risks of HRT?
The principal risks associated with HRT depend heavily on the type used and the individual patient profile. Estrogen-progestogen combined HRT carries a small increase in breast cancer risk relative to estrogen-only therapy in women who have had a hysterectomy. Venous thromboembolism risk is elevated with oral estrogen formulations compared to transdermal, though the absolute risk increase is small in low-risk women. Individual risk factors — age, time since menopause, cardiovascular history, and family history — significantly modify the risk picture.
What did the WHI study find, and is it still relevant?
The Women's Health Initiative (WHI) study published in 2002 found elevated risks for breast cancer, cardiovascular events, stroke, and VTE in women using combined estrogen-progestogen therapy. However, the WHI study population was older (average age 63, well past menopause onset) and used oral conjugated equine estrogen plus medroxyprogesterone acetate — formulations now known to carry higher VTE risk than transdermal estradiol. Current evidence from the timing hypothesis, re-analyses, and subsequent trials supports a more favorable risk profile when HRT is started closer to menopause onset in otherwise healthy women.
Does HRT protect against bone loss?
Yes. Estrogen is one of the primary regulators of bone turnover in women. Bone density declines accelerate significantly around menopause as estrogen levels fall. HRT consistently demonstrates preservation of bone mineral density and reduction in fracture risk in postmenopausal women. This is one of the strongest evidence-based non-symptomatic benefits of HRT.
Is transdermal estrogen safer than oral for VTE risk?
Current evidence strongly suggests transdermal estradiol carries a significantly lower VTE risk than oral estrogen formulations. Oral estrogen undergoes first-pass liver metabolism, increasing clotting factor production. Transdermal estrogen bypasses first-pass metabolism and has not shown a significant VTE signal in observational studies. Transdermal delivery is now preferred in clinical guidelines for women with VTE risk factors.
Does a woman need a clinician before starting HRT?
Yes. HRT requires a prescription and should be preceded by a clinical evaluation that includes a symptom assessment, health history, contraindication screening, and a discussion of formulation options. Contraindications to systemic estrogen include a history of estrogen-receptor-positive breast cancer, unexplained vaginal bleeding, active liver disease, and history of VTE in some formulations. A clinician determines the appropriate formulation, dose, and route for each patient.